Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Partial nephrectomy is even more critical in early-onset RCC

Clemmensen T et al. Human Pathology April 2018 25-31. https://doi.org/10.1016/j.humpath.2017.11.005

Key clinical point: Patients who develop RCC before age 47 typically have comorbidities that place them at an increased risk for chronic kidney disease and end-stage renal disease. Partial nephrectomy is even more critical to pursue if deemed feasible in this at-risk population. Only 2/96 (2.1%) patients in the early onset RCC group had disease recurrence.

Major finding: Compared to the control group, early onset RCC patients were more likely to undergo a partial nephrectomy (P = .002) and 78% of patients presented with stage 1a (52/91) or 1b (19/91) disease. In the control group, 67% of patients presented with stage 1a (234/500) or 1b (101/500) disease. In the early onset RCC group, 9/91 (9.9%) patients presented with stage 3 disease, compared to 120/500 (24%) patients in the control group.

Study details: A retrospective search of a surgical pathology database performed from 2011 to 2016 identified 598 RCCs in 576 patients. In the early onset RCC group, 98 (16.4%) RCCs occurred in 96 patients. The remaining 500 (83.6%) RCCs occurred in 480 patients older than 46 years, which comprised the control group.

Disclosures: The researchers had no relevant financial disclosures.

Source: Clemmensen T et al. Human Pathology April 2018 25-31. https://doi.org/10.1016/j.humpath.2017.11.005

Citation:

Clemmensen T et al. Human Pathology April 2018 25-31. https://doi.org/10.1016/j.humpath.2017.11.005

This Week's Must Reads

Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.

Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027

DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.

ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.

SRS can effectively control brain metastases in patients with RCC, Wardak Z et al. Clin Genitourin Cancer. 2018 Nov 20. doi: 10.1016/j.clgc.2018.11.006.

Must Reads in Renal Cell Carcinoma

Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.

Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027

DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.

ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.

SRS can effectively control brain metastases in patients with RCC, Wardak Z et al. Clin Genitourin Cancer. 2018 Nov 20. doi: 10.1016/j.clgc.2018.11.006.